- Home
- ERAS vs MANE Comparison
ERAS vs MANE Comparison
Compare ERAS & MANE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ERAS | MANE |
|---|---|---|
| Founded | 2018 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.0B |
| IPO Year | 2021 | 2026 |
Fundamental Metrics
Financial Performance| Metric | ERAS | MANE |
|---|---|---|
| Price | $16.98 | $156.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $24.11 | ★ $178.17 |
| AVG Volume (30 Days) | ★ 4.5M | 588.9K |
| Earning Date | 11-24-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.23 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.46 | $35.43 |
| 52 Week High | $24.28 | $152.82 |
Technical Indicators
Market Signals| Indicator | ERAS | MANE |
|---|---|---|
| Relative Strength Index (RSI) | 61.85 | 65.89 |
| Support Level | $13.19 | $92.62 |
| Resistance Level | $18.71 | N/A |
| Average True Range (ATR) | 1.14 | 8.15 |
| MACD | 0.24 | 0.80 |
| Stochastic Oscillator | 88.53 | 98.18 |
Price Performance
Historical ComparisonAbout ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
About MANE Veradermics Incorporated Common Stock
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.